ClinicalTrials.gg
RecruitingNCT04665206Updated Nov 17, 2026

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

A Phase 1/2 interventional study of VT3989 and Nivolumab & Ipilimumab in Solid Tumor, Adult, Mesothelioma and NSCLC, sponsored by Vivace Therapeutics, Inc. Recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Vivace Therapeutics, Inc · Phase 1/2, Interventional, and Treatment

How we know · 27 judgments · 4 readings being read again

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 7 months later.
Updated Nov 17, 2026Site recruiting status changedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
474
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Mesothelioma with a site in United States — 35 open to participants now, 51 under way, 1 of them phase 3. Mesothelioma · United States.

Planned enrollment
7th of 165
474 · median 44
Started
2021
with 14 others
Phase 1/2
30 of 189
8 open now
Primary completion
2029-11
later than 40 of 50 live
Registered
139th of 189
by date

Among the 189 studies in Mesothelioma with a site in United States, this one is the 7th largest by planned enrollment of the 165 interventional ones that give a count, is one of 15 that started in 2021, is one of 30 in phase 1/2, reaches primary completion later than 40 of the 50 other live ones, and was the 139th registered.

Mesothelioma

305 studies on the registry are indexed under Mesothelioma; 59 are open to participants now.

Browse Mesothelioma studies →

Open to participants now

35 of the 189 studies in Mesothelioma with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Mesothelioma studies recruiting now, 32 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Mesothelioma with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Read the detailed description

Dose escalation (Part 1) will employ a traditional 3 + 3 design to assess safety of VT3989 in patients with metastatic solid tumors or mesothelioma. The 3 + 3 design will be implemented until the MTD or recommended phase 2 dose(s) and schedule(s) are determined. The MTD is defined as the highest dose level at which \< 33% of patients experience a dose limiting toxicity (DLT) during the first cycle of the study (Cycle 1).

Dose Expansion (Part 2) will further evaluate the safety and assess preliminary antitumor activity at the recommended phase 2 dose(s) and schedule(s) with up to 6 cohorts. Expansion cohorts 1 and 2 will enroll patients with mesothelioma of any site origin with or without NF2 mutations. Expansion cohort 3 will enroll non-pleural mesothelioma patients. Expansion cohort 4 will enroll solid tumor patients with clearly inactivating NF2 mutations/alterations or YAP/TAZ gene rearrangements. Cohort 5 will enroll pleural mesothelioma patients.

Combination part (Part 3) includes three cohorts. Cohort A will enroll mesothelioma patients who will receive VT3989 in combination with immunotherapy (nivolumab plus ipilimumab). Cohort B will enroll NSCLC patients whose tumors have exon 19 deletion or exon 21 L858R mutation and will receive VT3989 in combination with targeted therapy (Osimertinib). Cohort C will enroll pleural mesothelioma patients who will receive VT3989 in combination with chemotherapy (pemetrexed plus carboplatin).

03

Conditions studied

  • Solid Tumor, Adult
  • Mesothelioma
  • NSCLC
  • Pleural Mesothelioma
  • Non-Pleural Mesothelioma
  • Non Small Cell Lung Cancer
  • Epithelioid Hemangioendothelioma (EHE)
  • Adenoma
  • Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Neoplasms by Histologic Type
  • Neoplasms, Mesothelial

Keywords

  • TEAD
  • YAP/TAZ
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 3 Combination Cohort A: Patients with diagnosed, or unresectable malignant mesothelioma (including both pleural and non-pleural) who have not received systemic therapy.
  • Part 3 Combination Cohort B: Patients with pathologically diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib.
  • Part 3 Combination Cohort C: Patients with pathologically diagnosed metastatic or unresectable malignant pleural mesothelioma who have not received systemic chemotherapy.
  • Part 1: Evaluable or per v1.1 or
  • Part 2 and 3: Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma.
  • : 0-1.
  • Adequate organ functions, including the liver, kidneys, and hematopoietic system.

Exclusion criteria

Exclusion Criteria:

  • Active or primary CNS (central nervous system) tumors.
  • History of
  • Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
  • Known positive or active or
  • cardiovascular disease and prior exposure to cardiotoxic agents.
  • (QTcF) interval > 470 msec (using Fridericia's correction formula).
  • Additional active that may confound the assessment of the study endpoints
  • Women who are pregnant or breastfeeding
  • Unwilling or unable to use highly effective measures.
  • Prior treatment with TEAD inhibitor, except for EHE patients.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
474 participants (estimated)

Study arms

  • Experimental
    VT3989 Dose Escalation [Not Recruiting]

    VT3989 dosed orally in 21 or 28 day cycles. Patients will be enrolled into escalating dose levels during the Dose Escalation Phase

    Drug: VT3989

  • Experimental
    Dose Expansion [Not Recruiting]

    VT3989 dosed in 21 or 28 day cycles in patients with refractory metastatic solid tumors or mesothelioma.

    Drug: VT3989

  • Experimental
    Combination [Recruiting]

    For Cohort A and B, VT3989 dosed in 28 day cycles in patients with metastatic solid tumors or mesothelioma, in combination with immunotherapy (nivolumab/ipilimumab) or targeted therapy (osimertinib). For Cohort C, VT3989 dosed in 21 day cycles in patients with mesothelioma in combination with chemotherapy (pemetrexed+carboplatin) for 4-6 cycles, then continuing VT3989 as monotherapy on 28-day cycle.

    Drug: VT3989 · Drug: Nivolumab & Ipilimumab · Drug: Osimertinib · Drug: Pemetrexed/Carboplatin

Interventions

  • DrugVT3989

    25, 50, 100, 150 or 200 mg for oral administration.

  • DrugNivolumab & Ipilimumab

    Drug pages: NivolumabBeing read again: the record changed after it was read.Studies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IpilimumabBeing read again: the record changed after it was read.Studies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nivolumab infusion - 360 mg every 3 weeks, 30-minute intravenous infusion Ipilimumab infusion - 1 mg/kg every 6 weeks, 30-minute intravenous infusion

  • 40 or 80 mg tablets for oral administration

  • DrugPemetrexed/Carboplatin

    Drug pages: PemetrexedBeing read again: the record changed after it was read.Studies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CarboplatinBeing read again: the record changed after it was read.Studies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pemetrexed infusion: 500 mg/m2 intravenous infusion Carboplatin infusion: AUC 5.0 intravenous infusion

06

What researchers measure

Primary outcomes

  1. Occurrence of Dose Limiting Toxicity

    Incidence of Adverse and Serious Adverse Events

    Time frame: over the first 21 days of dosing

  2. Occurrence of General Toxicity

    Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety evaluations

    Time frame: through study completion, an average of 30 months

Secondary outcomes

  1. Tumor Response

    Determined by RECIST v1.1 or modified RECIST v1.1

    Time frame: through study completion, an average of 30 months

  2. Pharmacokinetic Evaluation - Cmax

    Peak plasma concentration of VT3989

    Time frame: for first 6 cycles

  3. Pharmacokinetic Evaluation - Tmax

    Time to reach peak plasma concentration of VT3989

    Time frame: for first 6 cycles

  4. Pharmacokinetic Evaluation - Half-life

    Time required for the plasma concentration of VT3989 to reduce by half after reaching peak

    Time frame: for first 6 cycles

  5. Overall survival

    The overall survival of the enrolled patients from starting VT3989 treatment

    Time frame: At 6, 12, 18 and 24 months

  6. Progression free survival

    The progression free survival of the enrolled patients from starting VT3989 treatment

    Time frame: At 6, 12, 18 and 24 months

  7. Quality of life assessment (Part 2, expansion cohort 3, 4, and 5)

    Assessing the Quality of life changes via patient reported outcomes

    Time frame: Through study completion, an average of 30 months

07

Study locations

11 of 12 sites recruiting
08

References and documents

Publications

  • Yap TA, Kwiatkowski DJ, Dagogo-Jack I, Offin M, Zauderer MG, Kratzke R, Desai J, Body A, Millward M, Tolcher AW, Raghav KPS, Thurston A, Post L, Dorr FA, Tang TT, Li Y, Sharma N, Kindler HL. YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial. Nat Med. 2025 Dec;31(12):4281-4290. doi: 10.1038/s41591-025-04029-3. Epub 2025 Oct 19. PubMed 41111090 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Nov 2029, 103 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2020
First posted
Dec 11, 2020
StartActual
Mar 24, 2021
Primary completionEst.
Nov 2, 2029
CompletionEst.
Mar 2, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Linear Clinical Research is now Terminated
Nov 17, 2026
Enrollment
434→474
Nov 17, 2026
Eligibility
1 inclusion criterion edited, 1 added; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • AddedPart 1: Evaluable or measurable disease per RECIST v1.1 or mRECIST
  • EditedPart 2 and 3: Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma.
Exclusion criteria
  • AddedUnwilling or unable to use highly effective contraceptive measures.
  • EditedPrior treatment with TEAD inhibitor, except for EHE patients.
Nov 17, 2026
Site contacts
Changed at 12 sites. See the sites
Show 12 sites
  • UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, United StatesContact h•••@inclin.com · •••7437→L•••@ucsf.edu · •••7866
  • University of Chicago Medical Center · Chicago, United StatesContact h•••@inclin.com · •••7437→c•••@bsd.uchicago.edu · •••8222
  • Massachusetts General Hospital · Boston, United StatesContact h•••@inclin.com · •••7437→r•••@massgeneralbrigham.org · •••1134
  • Dana-Farber Cancer Institute · Boston, United StatesContact h•••@inclin.com · •••7437→d•••@dfci.harvard.edu · •••3324
  • M Health Fairview University of Minnesota Medical Center · Minneapolis, United StatesContact h•••@inclin.com · •••7437→k•••@umn.edu · •••8383
  • Memorial Sloan Kettering Cancer Center · New York, United StatesContact h•••@inclin.com · •••7437→o•••@mskcc.org · •••3763
  • MD Anderson Cancer Center · Houston, United StatesContact h•••@inclin.com · •••7437→T•••@mdanderson.org · •••1784Contact added T•••@mdanderson.org
  • NEXT Oncology · San Antonio, United StatesContact h•••@inclin.com · •••7437→J•••@nextoncology.com · •••9539
  • Virginia Cancer Specialists, PC · Arlington, United StatesContact h•••@inclin.com · •••7437→a•••@nextoncology.com · •••4510
  • Monash Health · Clayton, AustraliaContact h•••@inclin.com · •••7437→e•••@monashhealth.org · •••9510
  • Peter MacCullum Cancer Centre · Melbourne, AustraliaContact h•••@inclin.com · •••7437→P•••@petermac.org · •••5000
  • Linear Clinical Research · Nedlands, AustraliaContact removed h•••@inclin.com · •••7437
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Linear Clinical Research is now Terminated
    Enrollment 434→474
    Eligibility 1 inclusion criterion edited, 1 added; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • AddedPart 1: Evaluable or measurable disease per RECIST v1.1 or mRECIST
    • EditedPart 2 and 3: Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma.
    Exclusion criteria
    • AddedUnwilling or unable to use highly effective contraceptive measures.
    • EditedPrior treatment with TEAD inhibitor, except for EHE patients.
    Site contacts Changed at 12 sites. See the sites
    Show 12 sites
    • UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, United StatesContact h•••@inclin.com · •••7437→L•••@ucsf.edu · •••7866
    • University of Chicago Medical Center · Chicago, United StatesContact h•••@inclin.com · •••7437→c•••@bsd.uchicago.edu · •••8222
    • Massachusetts General Hospital · Boston, United StatesContact h•••@inclin.com · •••7437→r•••@massgeneralbrigham.org · •••1134
    • Dana-Farber Cancer Institute · Boston, United StatesContact h•••@inclin.com · •••7437→d•••@dfci.harvard.edu · •••3324
    • M Health Fairview University of Minnesota Medical Center · Minneapolis, United StatesContact h•••@inclin.com · •••7437→k•••@umn.edu · •••8383
    • Memorial Sloan Kettering Cancer Center · New York, United StatesContact h•••@inclin.com · •••7437→o•••@mskcc.org · •••3763
    • MD Anderson Cancer Center · Houston, United StatesContact h•••@inclin.com · •••7437→T•••@mdanderson.org · •••1784Contact added T•••@mdanderson.org
    • NEXT Oncology · San Antonio, United StatesContact h•••@inclin.com · •••7437→J•••@nextoncology.com · •••9539
    • Virginia Cancer Specialists, PC · Arlington, United StatesContact h•••@inclin.com · •••7437→a•••@nextoncology.com · •••4510
    • Monash Health · Clayton, AustraliaContact h•••@inclin.com · •••7437→e•••@monashhealth.org · •••9510
    • Peter MacCullum Cancer Centre · Melbourne, AustraliaContact h•••@inclin.com · •••7437→P•••@petermac.org · •••5000
    • Linear Clinical Research · Nedlands, AustraliaContact removed h•••@inclin.com · •••7437
    + 5 other changes: index terms, verification date, description, conditions and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04665206
Lead sponsor
Vivace Therapeutics, Inc
Responsible party
Sponsor
First posted
Dec 11, 2020
Start date
Mar 24, 2021
Primary completion
Nov 2, 2029 (estimated)
Completion
Mar 2, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Heather Fritz
Contact
hfritz@inclin.com
650-627-7437
Neelesh Sharma, MD
Contact
nsharma@vivacetherapeutics.com
732-476-4978
Neelesh Sharma, MD
study director · Vivace Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion